Cue Biopharma is trading 6.7% down at $30.38 as investors lock in gains following a sharp multi-month rally triggered by its April 2026 reverse split.
- The stock's recent upward momentum was supported by a 1-for-30 reverse split and positive licensing and financing developments.
- Today's decline appears to be driven by profit-taking and inherent volatility in a recently repriced biotech, as there are no fresh company-specific headlines.
- The downward move occurs against a backdrop of mixed broader markets, even as the general biotech sector remains relatively strong.